Harbor Capital Advisors Inc. Purchases Shares of 9,936 Guardant Health, Inc. $GH

Harbor Capital Advisors Inc. purchased a new position in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,936 shares of the company’s stock, valued at approximately $1,015,000.

A number of other large investors have also modified their holdings of GH. Chesapeake Asset Management LLC acquired a new stake in Guardant Health in the 4th quarter worth approximately $28,000. First Pacific Financial acquired a new position in Guardant Health during the 4th quarter valued at approximately $43,000. Sound Income Strategies LLC purchased a new position in shares of Guardant Health in the third quarter worth $38,000. Optiver Holding B.V. raised its holdings in shares of Guardant Health by 153.5% in the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after buying an additional 465 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Guardant Health by 38.8% during the fourth quarter. GAMMA Investing LLC now owns 808 shares of the company’s stock worth $83,000 after buying an additional 226 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $93.83 on Monday. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $120.74. The business has a 50 day moving average of $97.07 and a two-hundred day moving average of $92.94. The company has a market capitalization of $12.31 billion, a PE ratio of -28.35 and a beta of 1.64.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same quarter last year, the firm earned ($0.62) earnings per share. Guardant Health’s revenue for the quarter was up 39.4% on a year-over-year basis. Equities research analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Medina Manuel Hidalgo sold 1,300 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the sale, the director directly owned 1,193 shares in the company, valued at $109,207.22. This trade represents a 52.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Brian Bell sold 3,000 shares of Guardant Health stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the completion of the transaction, the chief financial officer owned 43,601 shares of the company’s stock, valued at approximately $3,795,031.04. This represents a 6.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 23,250 shares of company stock worth $2,512,917 in the last ninety days. Corporate insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GH. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Friday, February 20th. Leerink Partners lifted their price target on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 20th. UBS Group reiterated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research note on Friday, January 30th. Guggenheim increased their price objective on Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, Wells Fargo & Company raised their price objective on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, February 20th. Twenty equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $125.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.